Galapagos Finishes Enrollment of Patients with Ulcerative Colitis for IBD Trial

Galapagos Finishes Enrollment of Patients with Ulcerative Colitis for IBD Trial
Galapagos NV recently announced that the company has completed recruitment of patients with ulcerative colitis for its phase 2 proof-of-concept study designed to evaluate GLPG1205 as a possible therapy for inflammatory bowel diseases (IBD). Galapagos is now ready to initiate the study and expects to release the first results of the clinical trial during the start of next year. The study

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *